Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | NOX2: a potential immune checkpoint for inhibition in AML

Anna Martner • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Checkpoint inhibitors

Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.

More from Anna Martner

Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival 1:50
Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
Anna Martner • 25 Feb 2019
What are the advantages of using histamine dihydrochloride together with immunotherapy? 1:50
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Anna Martner • 24 Feb 2017
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC 6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals